Compare SLDP & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | PSNL |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | 230 | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.7M | 729.1M |
| IPO Year | N/A | 2019 |
| Metric | SLDP | PSNL |
|---|---|---|
| Price | $3.14 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $13.88 | $16.94 |
| Revenue Next Year | $10.00 | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.68 | $2.83 |
| 52 Week High | $8.86 | $11.50 |
| Indicator | SLDP | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 41.29 |
| Support Level | $2.94 | $6.89 |
| Resistance Level | $4.70 | $9.64 |
| Average True Range (ATR) | 0.17 | 0.55 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 30.77 | 24.52 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.